The resistance of malaria parasites to existing drugs carries on growing and progressively
limiting our ability to manage this severe disease and finally lead to a massive global health …

Malaria has been teasing human populations from a long time. Presently, several classes of
antimalarial drugs are available in market, but the issues of toxicity, lower efficacy and the …

In spite of recent efforts to eradicate malaria in the world, this parasitic disease is still
considered a major public health problem, with a total of 216 million cases of malaria and …

A convenient approach to antimalarial drug discovery is the use of the organic scaffold of a
known antimalarial drug and an organometallic moiety to alter its unwanted properties …

Ferroquine (FQ, SSR97193) is currently the most advanced organometallic drug candidate
and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This …

Malaria is a worldwide neglected infectious disease that, despite decades of research
invested in its prevention and treatment, remains one of the main causes of mortality and …

Inhibition of hemozoin biocrystallization is considered the main mechanism of action of 4-
aminoquinoline antimalarials including chloroquine (CQ) but cannot fully explain the activity …

Background Ferroquine (SSR97193) is a candidate anti-malarial currently undergoing
clinical trials for malaria. To better understand its pharmacokinetic (PK) and …

Ferroquine (FQ or SR97193) is a novel antimalarial drug candidate, currently in
development at Sanofi-Aventis. In contrast to conventional drugs, FQ is the first …

Background Artemisinin-based combination therapies (ACTs) are the recommended first-
line treatment for uncomplicated Plasmodium falciparum malaria. Ferroquine is a new …